Wire · opportunities
Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 11 October 2026 · Fusion42 review
Freenome is presenting validation data showing improved sensitivity for its updated blood-based colorectal cancer (CRC) screening test, SimpleScreen CRC, which demonstrates significant performance enhancement in detecting advanced precancerous lesions with 80.4% sensitivity and 90% specificity. The updated test received FDA approval in July 2026 and was commercially launched in the US by Abbott Cancer Diagnostics.
This Wire brief sits within Fusion42's coverage of Health, and 5 sources have reported it between 30 Sep 2026 and 11 Oct 2026.
◆ ◆ The Wire takeaway
You must revaluate the standards for non-invasive colorectal cancer screening now improved by Freenome's blood test. This opens a market opportunity in early cancer detection targeting unscreened populations with better-performing, less invasive tests.
◆ Coverage
5 sources · first reported 30 Sep 2026 · latest 11 Oct 2026
◆ Related on Wire
◆ Topics